The ClinGen Evidence Repository is an **FDA-recognized human genetic variant database** containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000540.2(RYR1):c.7310C>T (p.Ala2437Val)

Version: 1.1

CA024756

133197 (ClinVar)

Gene: RYR1 (HGNC:6261)
Condition: malignant hyperthermia, susceptibility to, 1 (MONDO:0007783)
Inheritance Mode: Autosomal dominant inheritance
UUID: b4cbc77a-3fee-4506-8590-ba240224bdb4
Approved on: 2023/4/6
Published on: 2023/4/6

HGVS expressions

NM_000540.2:c.7310C>T
NM_000540.2(RYR1):c.7310C>T (p.Ala2437Val)
NC_000019.10:g.38500003C>T
CM000681.2:g.38500003C>T
NC_000019.9:g.38990643C>T
CM000681.1:g.38990643C>T
NC_000019.8:g.43682483C>T
NG_008866.1:g.71304C>T
ENST00000599547.6:c.7310C>T
ENST00000359596.8:c.7310C>T
ENST00000355481.8:c.7310C>T
ENST00000359596.7:c.7310C>T
ENST00000360985.7:c.7307C>T
ENST00000594335.5:c.762C>T
NM_001042723.1:c.7310C>T
NM_000540.3:c.7310C>T
NM_001042723.2:c.7310C>T

Likely Pathogenic

Met criteria codes 3
PM1 PP3_Moderate PS4_Moderate

Not Met criteria codes 3
BA1 BS1 BP4

Evidence Links 0

Expert Panel
Malignant Hyperthermia Susceptibility VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Malignant Hyperthermia Susceptibility VCEP

This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in

making management decisions. This sequence variant predicts a substitution of alanine with valine at codon 2437 of the RYR1 protein, p.(Ala2437Val). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been reported in three unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, two of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID:15448513, personal communication, Leeds MH Unit, MH Investigation Unit (MHIU), UHN, Toronto). No functional studies were identified for this variant. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.917) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Likely Pathogenic. Criteria implemented: PS4_Moderate, PM1, PP3_Moderate.

Met criteria codes

PM1	✔	This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704).
PP3_Moderate	✔	A REVEL score >0.85 (0.917) supports a pathogenic status for this variant, PP3_Moderate.
PS4_Moderate	✔	This variant has been reported in three unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, two of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID:15448513, personal communication, Leeds MH Unit, MH Investigation Unit (MHIU), UHN, Toronto).

Not Met criteria codes

BA1	✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1	✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4	✖	No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

Curation History

Showing 1 to 2 of 2 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.